Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume 100, Issue 1, Pages 53-58Publisher
ELSEVIER SCIENCE INC
DOI: 10.1002/jps.22253
Keywords
pharmacokinetics; pharmacokinetics/pharmacodynamics; physiological model; population pharmacokinetics/pharmacodynamics; pediatric; elderly; inclusions; ADME; clinical pharmacokinetics
Funding
- NCATS NIH HHS [UL1 TR000423] Funding Source: Medline
- NCRR NIH HHS [UL1 RR025014] Funding Source: Medline
- NIAID NIH HHS [R01 AI077390, R01 AI052663, R01 AI077390-02, R01 AI077390-02S1, AI 077390] Funding Source: Medline
- NIGMS NIH HHS [R01 GM062883, R01 GM062883-04] Funding Source: Medline
- NIMH NIH HHS [R43 MH086351, MH086351, R43 MH086351-02] Funding Source: Medline
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000423] Funding Source: NIH RePORTER
- NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077390, R01AI052663] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062883] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF MENTAL HEALTH [R43MH086351] Funding Source: NIH RePORTER
Ask authors/readers for more resources
In spite of the recent advances in technology to optimize the absorption, distribution, metabolism and elimination (ADME) properties of new and promising medicinal products to reduce clinical failures, the investigation of drug disposition in the pediatric and elderly populations continues to be under evaluated. With the increasing prevalence of aging populations world-wide, there is a growing concern from health care providers, regulators and the general public that drug delivery is still less than optimal for the vulnerable patient populations likely to be more sensitive to adverse effects of the new investigational drugs. This review of the ClinicalTrials.gov database revealed a rapidly increasing number of clinical trials and a trend towards wider inclusion criteria of the elderly population in clinical trials over the past 10 years. However, when we summarized trials by drug delivery, biological platforms, and disease categories, less than 10% of these trials included pharmacokinetic evaluation in elderly subjects greater than 65 years of age, and less than 4% included pharmacokinetic evaluation in children less than 17 years of age. Across the various disease areas, the percentage of trials that included pharmacokinetic evaluation in the children and elderly has remained low and is consistently less than the studies that included the younger 18 to 65 age group. Therefore, it is not known whether the right information is being generated from the growing number of clinical trials to guide optimal dosing recommendations in special patient populations. (C) 2010 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 100:53-58, 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available